Teriflunomide (Aubagio®)

Assessment Status Assessment process complete
Drug Teriflunomide
Brand Aubagio®
Indication For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).
Assessment Process
Rapid review commissioned 27/08/2013
Rapid review completed 20/09/2013
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 25/11/2013
NCPE assessment completed 19/06/2014
NCPE assessment outcome Reimbursement Not Recommended.

The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.

Technical Summary

The HSE has approved reimbursement following price negotiations-September 2014